New Tool Predicts Multiple Myeloma Risk & Guides Treatment Decisions | Dana-Farber Cancer Institute

A new, freely available online tool is offering more precise predictions about the progression of smoldering multiple myeloma, a precursor condition to active cancer. Developed by investigators at Dana-Farber Cancer Institute, the tool – called PANGEA-SMM – aims to identify patients at genuine risk of developing multiple myeloma, helping to ensure they receive timely treatment, while sparing those with slower-progressing disease from unnecessary interventions.

Understanding Smoldering Multiple Myeloma

Multiple myeloma is a cancer that forms in plasma cells, a type of white blood cell. Smoldering multiple myeloma (SMM) is an early stage where abnormal plasma cells are present, but aren’t yet causing the symptoms associated with active myeloma. Not everyone with SMM will develop full-blown cancer; the condition can remain stable for years, or even a lifetime. However, for those who do progress, early intervention can significantly improve outcomes. The challenge lies in accurately identifying who needs treatment and who can safely be monitored.

Current methods for assessing risk rely on a single snapshot of a patient’s lab results. PANGEA-SMM, however, takes a dynamic approach, tracking changes in key biomarkers over time. Here’s a crucial distinction, as the rate of change can be a more reliable indicator of progression than a single measurement. The biomarkers used – M-protein levels, serum free light chain ratios, creatinine levels, and hemoglobin levels – are all routinely measured in standard SMM follow-up, making the tool widely accessible.

How PANGEA-SMM Works: A Dynamic Assessment

The tool’s developers published their findings in Nature Medicine, detailing a study involving over 2,300 patients with SMM from seven international centers. Researchers found that four evolving biomarkers were particularly strong predictors of progression: an increase of 0.2 g/dL or more in M-protein, a 20% or greater increase in the involved/uninvolved serum free light chain ratio, a creatinine increase exceeding 25%, and a hemoglobin decrease of 1.5 g/dL or more.

PANGEA-SMM analyzes these biomarkers, not as static values, but as trajectories – observing the speed and direction of change. According to the study, the tool outperforms existing models, including the widely used 20/2/20 criteria and the International Myeloma Working Group (IMWG) risk stratification system, with a C-statistic of 0.79. Even without a complete biomarker history (C-statistic of 0.78) or a recent bone marrow biopsy (C-statistic of 0.78), PANGEA-SMM maintains a high degree of accuracy. A C-statistic measures the tool’s ability to discriminate between patients who will and will not progress.

The Limitations of Prediction and the Importance of Monitoring

It’s important to emphasize that even the most sophisticated predictive tool isn’t perfect. PANGEA-SMM, while more accurate than previous methods, doesn’t eliminate uncertainty. The study acknowledges that predicting progression from SMM remains challenging due to the biological heterogeneity of the disease. Correlation does not equal causation; the biomarkers identified are associated with progression, but don’t necessarily cause it.

the study population was primarily drawn from the Dana-Farber Cancer Institute and other specialized centers. This raises questions about how well the tool will perform in more diverse populations and in community-based settings. Ongoing validation and real-world implementation studies will be crucial to address these concerns. The tool is intended to aid clinical decision-making, not replace it. Regular monitoring and individualized assessment remain essential components of SMM management.

What This Means for Patients and Clinicians

The availability of PANGEA-SMM represents a significant step forward in the management of smoldering multiple myeloma. For patients, it offers the potential for more personalized care, reducing the anxiety associated with uncertainty and minimizing the risk of unnecessary treatment. For clinicians, it provides a more refined tool for risk stratification, enabling them to create more informed decisions about when to initiate therapy. The tool is freely accessible online, making it available to healthcare providers worldwide. Dana-Farber’s news release confirms the tool is available for immediate use.

The development of PANGEA-SMM also highlights the growing importance of dynamic risk assessment in cancer care. By tracking changes in biomarkers over time, clinicians can gain a more nuanced understanding of disease progression and tailor treatment strategies accordingly. This approach is likely to be applied to other types of cancer in the future.

The Ongoing Evolution of Multiple Myeloma Management

The introduction of PANGEA-SMM is part of a broader trend toward earlier detection and intervention in multiple myeloma. The Dana-Farber team behind the tool is also focused on developing strategies to intercept the disease before it becomes symptomatic. Dr. Irene Ghobrial, Director of the Center for Early Detection and Interception of Blood Cancers at Dana-Farber, emphasizes the necessitate for a “unified, straightforward, and precise risk stratification model” to facilitate the implementation of these therapeutic strategies.

Looking ahead, further research is needed to identify new biomarkers and refine existing risk models. Longitudinal studies, like the one that informed the development of PANGEA-SMM, will be essential to track disease progression and evaluate the effectiveness of different interventions. The ultimate goal is to improve patient outcomes and reduce the burden of multiple myeloma.

Next Steps: Continued Validation and Implementation

The PANGEA-SMM tool is now available for use, but its journey doesn’t end here. Researchers are actively encouraging clinicians to utilize the tool and provide feedback. Ongoing data collection and analysis will be crucial to further validate its performance and identify areas for improvement. Expect to see continued refinement of the tool as more data becomes available and our understanding of smoldering multiple myeloma evolves.